The published record describes GHRP-2 most often paired with a growth hormone releasing hormone (GHRH) analog such as CJC-1295 because the two act on separate pituitary pathways and reinforce one another. GHRP-2 signals through the ghrelin receptor and also suppresses somatostatin, the hormone that normally brakes GH output, while CJC-1295 mimics GHRH and drives the somatotroph cells to synthesize and release GH. Neither peptide is FDA-approved for this use, and both are sold in the United States as Research Use Only compounds, so what follows documents protocols reported in the literature rather than any approved therapy.
GHRP-2 and CJC-1295 are co-administered because GHRP-2 triggers GH release and lifts somatostatin inhibition while CJC-1295 supplies a GHRH signal, producing a supra-additive GH pulse that neither research-only, non-FDA-approved peptide generates alone.
The rationale in the literature rests on the pituitary carrying two independent levers for growth hormone release, each answering to a different molecule. A GHRH analog loads and primes the somatotrophs through the cyclic AMP cascade, while a growth hormone releasing peptide fires a separate calcium-dependent signal and at the same time releases the somatostatin brake. Pulling both levers at once yields a pulse noticeably larger than either produces alone, and because it stays a discrete pulse rather than a flat elevation, the record frames it as a closer imitation of the body's own episodic secretion.
The two peptides act on distinct receptors, CJC-1295 on the GHRH receptor and GHRP-2 on the ghrelin/growth hormone secretagogue receptor, so combining them primes the somatotrophs, lifts somatostatin inhibition, and triggers release together for a pulse larger than either alone.
Although both peptides raise growth hormone, the published pharmacology places them on entirely different receptors with different character. The GHRH analog sets how ready and loaded the pituitary is, while the secretagogue sets the amplitude and timing of the actual pulse.
| Property | CJC-1295 (GHRH analog) | GHRP-2 (secretagogue) |
|---|---|---|
| Receptor | GHRH receptor | Ghrelin / GHS receptor |
| Duration | Days in DAC form (albumin-bound) | Hours; sharp release pulse |
| Role | Sustains readiness, raises baseline signal | Sets pulse amplitude and timing |
| Off-target hormones | Minimal effect on cortisol/prolactin | Can nudge appetite, cortisol, prolactin |
CJC-1295 is a long-lived GHRH-receptor analog that in its Drug Affinity Complex form persists for days and sustains pituitary readiness, whereas GHRP-2 is a short-acting ghrelin-receptor hexapeptide that clears within hours and delivers a sharp release pulse.
The defining feature of the pairing is synergy: together the peptides release more growth hormone than the arithmetic sum of what each releases alone, an effect the literature calls supra-additive. The two cascades converge on the same somatotrophs while the secretagogue lifts somatostatin, so the pituitary answers the GHRH signal with far less resistance than it normally would.
Co-administration of a GHRH analog and GHRP-2 produces a supra-additive growth hormone pulse, repeatedly reported as several times larger than either agent alone and raising circulating IGF-1, though the response plateaus once the somatotrophs' finite releasable pool is saturated.
Protocols in the research and practitioner literature treat timing as mattering as much as amount, and they center on a saturation dose rather than escalation. GHRP-2's pituitary effect plateaus near one hundred micrograms, so reported protocols keep the dose modest because pushing past saturation mostly adds cortisol and prolactin rather than growth hormone.
Described protocols pair the two peptides in a single subcutaneous injection at roughly 100 micrograms each, timed on an empty stomach and often at bedtime to align with the nocturnal GH surge, with GHRP-2's effect plateauing near the 100-microgram saturation dose.
Stacking two growth hormone secretagogues amplifies the risks along with the intended effect, and the published record grades them from mild and transient to serious and theoretical. The most consequential concern is that growth hormone and the IGF-1 it drives are growth-promoting signals, so a known or suspected malignancy is treated as a firm contraindication.
Beyond mild transient effects like water retention and joint aching, stacked secretagogues can raise fasting glucose and reduce insulin sensitivity, and because sustained GH and IGF-1 are growth-promoting, a known or suspected malignancy is treated as a firm contraindication.
The Drug Affinity Complex, or DAC, is a chemical attachment that binds CJC-1295 to serum albumin and stretches its half-life from minutes to roughly six to eight days, and that single difference reshapes how the peptide is combined. It determines dosing frequency, how tightly the two peptides need to be timed together, and whether the protocol aims to imitate natural pulses or to sustain an elevated floor.
The Drug Affinity Complex extends CJC-1295's half-life from minutes to roughly six to eight days, so the DAC form is dosed once or twice weekly as a steady GH floor while the non-DAC modified GRF 1-29 clears within about thirty minutes and is paired dose-for-dose with GHRP-2 to mimic a natural pulse.
Responsible use in the literature is bounded by measurement rather than by feel, and the central biomarker is insulin-like growth factor 1. Because growth hormone is released in short pulses that a single blood draw can miss, IGF-1 gives a stable, integrated readout used to keep the response inside an age-appropriate physiological range rather than a supraphysiological one.
Because these compounds are legally sold only for research and are not approved therapies, the reported safety boundary rests on medical supervision and laboratory monitoring, chiefly IGF-1 held to an age-appropriate range alongside periodic fasting glucose and HbA1c.
Growth hormone is not secreted at a constant level; the healthy pituitary releases it in discrete bursts, the largest during the first hours of deep sleep, and the troughs between pulses matter as much as the peaks because they let the receptors reset their sensitivity. How a combination interacts with that rhythm depends on whether it preserves the trough or erases it.
| Property | Short-acting pairing | Long-acting DAC form |
|---|---|---|
| GH signal | Sharp pulse, rises and falls in ~2 hours | Continuously elevated baseline |
| Natural trough | Preserved, receptors reset | Flattened |
| Timing | Bedtime dose reinforces nocturnal surge | Around-the-clock signal |
| Long-term concern | Pulse-preserving, favored for receptor health | Possible desensitization over extended use |
A short-acting GHRP-2 plus rapidly clearing GHRH pairing generates a roughly two-hour pulse that preserves the natural trough and reinforces the nocturnal surge, whereas a continuous DAC signal flattens the peaks and troughs and, over extended use, risks desensitizing the pituitary.
Educational use only. This article describes what the published scientific and clinical literature reports about GHRP-2. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
